INTERACTIONS BETWEEN ANTIRETROVIRAL AND PSYCHOACTIVE DRUGS
https://doi.org/10.22328/2077-9828-2014-6-1-19-27
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
References
1. Pokrovskii V.V., Ladnaya N.N., Sokolova E.V., Buravtsova E.V. Vich-infektsiya: Informatsionnyi byulleten' № 38.- M.: FNMTs po profilaktike i bor'be so SPIDom.- 2013.- 52 s.
2. VICh i narkomaniya v Rossii - problema v kvadrate // Meditsina i zdorov'e.- 2012.- № 6 (74).- S. 4.
3. Bartlett J.A., Buda J.J., Von S.B., et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overwiew // J. AIDS.- 2006.- Vol. 41, № 3.- P 323-331.
4. Llibre J.M., Schapiro J.M., Clotet B. Clinical implication of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virologic failure // Clin. Infect. Dis.- 2010.- Vol. 50, № 6.- P 872-881.
5. Wood E., Hogg R.S., Yip B., Dong W.W., Wynhoven B., Mo T., Brumme C.J., Montaner J.S., Harrigan P.R. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use // AIDS.- 2005. - Vol. 19, № 11. - P 1189-1195.
6. Parienti J.J., Ragland K., Lucht F., et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, is a predictor of HIV RNA replication // Clin. Infect. Dis.- 2010.- Vol. 50, № 8.- P 1192-1197
7. Zayavlenie o pozitsii «Potrebiteli in"ektsionnykh narkotikov i dostup k lecheniyu VICh»: Global'naya set' lyudei, zhivushchikh s VICh/SPIDom (The Global Network of People living with HIV/AIDS, GNP +), Mezhdunarodnoe soobshchestvo zhenshchin, zhivushchikh s VICh i SPIDom (The International Community of Women Living with HIV and AIDS, ICW), Amsterdam, London, oktyabr' 2005 g. - 2005.- 19 s. URL: http://www.icw.org/files/IDURU.pdf (data obrashcheniya 12.12.2013 g.)
8. Wood E., Kerr T., Tyndall M.W., Montaner J.S. A review of barriers and facilitators of HIV treatment among injection drug users // AIDS.- 2008.- Vol. 22, № 11.- P 1247-1256.
9. Chander G., Himelhoch S., Fleishman J.A., Hellinger J., Gaist P., Moore R.D., Gebo K.A. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use // AIDS Care. - 2009.- Vol. 21, № 5. - P. 655-663.
10. Lert F., Kazatchkine M.D. Antiretroviral HIV treatment and care for injecting drug users: An evidence-based overview // The International J. of Drug Policy.- 2007.- Vol. 18, № 4.- P. 255-261.
11. Grigoryan A., Hall H.I., Durant T., Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004 // PLoS One.- 2009.- № 4 (2).- R. 4445.
12. Lassila J., Aho I., Ristola M., Sutinen J.A. Large Proportion of Unknown Causes of Death // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013 - PE12/25.- P 127.
13. Vyaltsin S., Mikhailova N., Kalinina T. Analysis of Mortality among HIV-infected People in Orenburg // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013 - PE12/17.- P 124.
14. Orrell C. Antiretroviral adherence in a resource-poor setting // Curr HIV/AIDS Rep.- 2005.- Vol. 2, № 4.- P 171-176.
15. Lechenie i pomoshch' pri VICh/SPIDe. Klinicheskie protokoly dlya Evropeiskogo regiona VOZ.- VOZ, 2007.- Protokol 5 «VICh/SPID u potrebitelei in"ektsionnykh narkotikov: lechenie i pomoshch'».- S. 173-244.- URL: http://www.euro.who.int data/assets/pdf_file/0018/78111/E90840R.pdf (data obrashcheniya 15.12.2013).
16. Virus immunodefitsita cheloveka - meditsina: Rukovodstvo dlya vrachei / Pod red. N.A.Belyakova, A.G. Rakhmanovoi.- 2-e izd.- SPb.: Baltiiskii meditsinskii obrazovatel'nyi tsentr, 2011.- 656 s.
17. Spravochnaya sistema metodicheskoi podderzhki uchrezhdenii sotsial'nogo obsluzhivaniya semei i detei po voprosam profilaktiki zloupotrebleniya psikhoaktivnymi veshchestvami: Rukovodstvo / Komitet po sotsial'noi politike Sankt-Peterburga, 2011. - URL: http://www.kidantidrug.org/modules.php?name=News&file=article&sid=110 (data obrashcheniya 15.12.2013 g.).
18. Batler U.E. Pravo na zdorov'e i Konventsii OON o narkotikakh.- M.,2009.- 36 s.- URL: http://www.unodc.org/documents russia/Reports/WButler._Right_to_health_and_UN_conventions_on_narcotics_FINAL_RUS_ENG_www.pdf (data obrashcheniya 25.12.2013g.).
19. Evans-Jones J.G., Cottle L.E., Back D.J., Gibbons S., Beeching N.J., Carey P.B., Khoo S.H. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy // Clin Infect Dis. - 2010. - Vol. 50, № 10. - R 1419-1421.
20. VICh-infektsiya i SPID: Natsional'noe rukovodstvo / Pod red. V.V. Pokrovskogo.- M.: GEOTAR-Media, 2013.- 608 s.
21. Rosen M.I., Rigsby M.O., Dieckhaus K.D., Cramer J.A. Effects of illicit drug use on adherence to prescribed antiretroviral medication // American J. of Addiction.- 2003.- Vol. 12, № 5.- P 455-458.
22. Robison L.S., Westfall A.O., Saag M.S., Curtin C., Wang S.-S., Twyman R., Schwabe S. Short-term discontinuation of HAART regimens more common in vulnerable patient populations // AIDS Res. - 2008. - Vol. 24, № 11. - P 1347-1355.
23. Hendershot C.S., Stoner S.A., Simoni J.M., Pantalone D.W. Alcohol use and antiretroviral adherence: review and meta-analysis // JAIDS.- 2009.- Vol. 52, № 2.- P. 180-202.
24. Kampman K.M., Pettinati H., Lynch K.G., Dackis C., Sparkman T., Weigley C., O'Brien C.P. A pilot trial of topiramate for the treatment of cocaine dependence // Drug and Alcohol Dependence.- 2004.- Vol. 75, № 3.- P. 233-240.
25. McCance-Katz E.F., Kosten T.R., Jatlow P. Disulfiram effects on acute cocaine administration // Drug and Alcohol Dependence.- 1998.- Vol. 52, № 1.- P 27-39.
26. Bialer M., Doose D.R., Murthy B., Curtin C., Wang S.-S.; Twyman R., Schwabe S. Pharmacokinetic interactions of topiramate // Clinical Pharmacokinetics.- 2004.- Vol. 43, № 12.- P 763-780.
27. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence // Drug Safety.- 1999.- Vol.20, № 5.- P 427-435.
28. Jenkinson R.A., Clark N.C., Fry C.L., Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? // Addiction. - 2005.- Vol. 100, № 2.- R. 197-205.
29. Bulekov I.S. Narkopotreblenie kak glavnyi element nepriverzhennosti VAART. Mozhno li sformirovat' priverzhennost' u aktivnogo narkopotrebitelya // VICh-infektsiya i immunosupressii.- 2011.- T. 3, № 4, S. 20-23.
30. Uhlmann S., Milloy M.J., Kerr T., Zhang R., Guillemi S., Marsh D., Hogg R.S., Montaner J.S., Wood E. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users // Addiction. - 2010.- Vol. 105, № 5. - P 907-913.
31. Chander G., Himelhoch S., Moore R.D. Substance abuse and psychiatric disorders in HIV-positive patients: Epidemiology and impact on antiretroviral therapy // Drugs.- 2006.- Vol. 66, № 6.- P 769-789.
32. Wood E., Kerr T., Montaner J.S. HIV treatment, injection drug use, and illicit drug policies // Lancet.- 2007.- № 370 (9581).- P 8-10.
33. Ulyukin I.M., Dodonov K.N., Bolekhan V.N. Nekotorye nereshennye voprosy lecheniya opiinoi narkomanii na fone VICh-infektsii // Mediko-biologicheskie i sotsial'no-psikhologicheskie problemy bezopasnosti v chrezvychainykh situatsiyakh.- 2012.- № 2.- S. 53-59.
34. Serebrovskaya L.V., Popova A.A., Ivanova L.A., Khokhlova O.N. Novye vozmozhnosti opredeleniya CD4 T-limfotsitov u VICh-infitsirovannykh patsientov. Rekomendatsii // VICh-INFEKTsIYa: Informatsionnyi byulleten' № 37. - M.: FNMTs po profilaktike i bor'be so SPIDom.- 2013.- 32 s.
35. Fellay J., Boubaker K., Ledergerber B., Bernasconi E., Furrer H., Battegay M., Hirschel B., Vernazza P., Francioli P., Greub G., Flepp M., Telenti A. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study // Lancet.- 2001.- № 358 (9290).- R 1322-1327.
36. Dieleman J.P., Jambroes M., Gyssens I.C., Sturkenboom M.C., Stricker B.H., Mulder W.M., de Wolf F., Weverling G.J., Lange J.M., Reiss P., Brinkman K. ATHENA Study Group. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy // AIDS.- 2002.- Vol. 16, № 5.- R 737-745.
37. Bouhnik A.D., Preau M., Vincent E., Carrieri M.P., Gallais H., Lepeu G., Gastaut J.A., Moatti J.P., Spire B. MANIF 2000 Study Group. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy // Antiviral Therapy.- 2005.- Vol. 10, № 1.- P 53-61.
38. Cruess D.G., Douglas S.D., Petitto J.M., Leserman J., Ten Have T., Gettes D., Dub? B., Evans D.L. Association of depression, CD8+T lymphocytes and natural killer cell activity: implications for morbidity and mortality in human immunodeficiency virus disease // Current Psychiatry Report.- 2003.- Vol. 5, № 6.- P 445-450.
39. Schwarz B., Eisele L., Neumann T., Reinsch N., Schulze C., Warnke A., Holzendorf V., Hower M., Potthoff A., Brockmeyer N., Becker-Boost I., Kwirant F., Erbel R., Moebus S., Jockel K.-H., Schadendorf D., Esser S. Psychotropic Drugs Are Prescribed More Frequent in HIV-positive Patients Compared to the General Population - Data from Two German Prospective Cohorts; Heinz Nixdorf Recall Study and HIV HEART Study // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium. - 2013.- PE15/27.- P 159
40. Andrade Fuentes K., Manjarrez Tellez B., Gaytan Martinez J., et al. Tubular Dysfunction in HIV Infected Patients on Antiretroviral Therapy in a HIV Clinic in Mexico // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013.- PE11/12.- P 112
41. Saumoy M., Navarro A., Di Yacovo S., Vazquez-Vega G., Garcia-Yanez J.C., Sandoval Ramirez J.L., Mata-Marin J.A. Carotid Intimamedia Thickness Assessment in High Cardiovascular Risk HIV-infected Patients Randomized to an Intensive Intervention on Lifestyle versus Routine Care // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013.- PE11/16.- P 113.
42. Beato Prata M., Ventura C., Duque V., Saraiva da Cunha J.G. DRESS Syndrome Related to Raltegravir // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013.- PE11/21.- P 115.
43. Battalora L., Buchacz K., Armon C., Overton E.T., Hammer J., Patel P., Chmiel J.S., Wood K., Brooks J.T., Young B. Low Bone Mineral Density is Associated with Increased Risk of Incident Fracture in HIV-infected Adults // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013.- PS1/4.- P 8.
44. Dekoven M., Makin C., Slaff S., et al. Burden of Adverse Events (AEs) Associated with HIV Antiretroviral Therapy (ART) in the United States // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013.- PE11/18.- P 114.
45. Altice F.L., Kamarulzaman A., Soriano V.V., Schechter M., Friedland G.H. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs // Lancet.- 2010.- № 376 (9738).- P 367-387.
46. EACS (European AIDS Clinical Society) Guidelines Version 7.0, October 2013.- Berlin: Konigsdruck Service GmbH.- 2013.- 120 p. http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf (data obrashcheniya 25.12.2013).
47. Fichtenbaum C.J., Gerber J.G., Rosenkranz S.L., Segal Y., Aberg J.A., Blaschke T., Alston B., Fang F., Kosel B., Aweeka F. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 // AIDS.- 2002.- Vol.16, № 4.- P 569-577.
48. Piscitelli S.C., Burstein A.H., Welden N., et al. The effect of garlic supplements on the pharmacokinetics of saquinavir // Clin. Infect. Dis. - 2002.- Vol. 34, № 2.- P 234-238
49. Slain D., Amsden J.R., Khakoo R.A., Fisher M.A., Lalka D., Hobbs G.R. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers / // Pharmacotherapy.- 2005. - Vol. 25, № 2. - P 165-170
50. Ho Y.C., Shan L., Hosmane N.N., Gallicano K.D., Falloon J. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure // Cell.- 2013.- Vol. 155, № 3.- P 540-555
51. Katchman E., Savyon M., Chemtob D., Wang J., Laskey S.B., Rosenbloom D.I., Lai J., Blankson J.N., Siliciano J.D., Siliciano R.F. An Outbreak of Primary HIV Infection among Injecting Drug Users in Tel Aviv, Israel Associated with Changes in the Illicit Drug Use Practices // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013.- PS11/4.- P 32-33.
52. Materialy Konsul'tativnoi vstrechi NIDA/IAS «Profilaktika i lechenie VICh/SPIDa u potrebitelei narkotikov: global'naya perspektiva», Vashington, 11-12.01.2010 g.- NIDA/IAS.- 120 s.- URL: http://www.iasociety.org/Web/WebContent/File NIDA-IAS_2010_Meeting_Report_RU.pdf (data obrashcheniya 25.12.2013).
53. Proekt Gosudarstvennoi strategii protivodeistviya rasprostraneniyu zabolevaniya, vyzyvaemogo virusom immunodefitsita cheloveka, v Rossiiskoi Federatsii na period do 2020 goda.- URL: http://www.rosminzdrav.ru/news/2013/11/29/1-dekabrya-vsemirnyy-den-borby-so-spidom (data obrashcheniya 23.12.2013).
54. Korten V., Inan D., Yildirmak T., et al. Prevalence of Transmitted Drug Resistance (TDR) in Newly Diagnosed HIV-1 Infected Patients in Turkey // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013.- PE9/9.- P 94.
55. Pineda-Pena A.C., Ferreira F., Schrooten Y., et al. Drug Resistance in Newly Diagnosed HIV-1 Infected Patients in Leuven, Belgium from 1998 to 2011: Results from Routine Genotyping Testing // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium. - 2013.- PE9/6.- P 95.
56. Schmidt D., Kollan C., Fatkenheuer G., et al. Proportion of Transmitted and Acquired HIV Drug Resistance in a Long Term Observational Cohort in Germany // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013.- PE9/11.- P 95-96.
57. Hofstra M., Sauvageot N., Albert J., et al. Increasing Number of HIV-1 Diagnoses with Transmitted Drug Resistance across Europe despite Stable Prevalence / // 14th European AIDS Conference, 16-19.10.2013, Brussels, Belgium.- 2013.- PS2/1.- P 9.
58. Belyakov N.A., Levina O.S., Rybnikov V.Yu. Formirovanie priverzhennosti k lecheniyu u bol'nykh s VICh-infektsiei // VICh-infektsiya i immunosupressii.- 2013.- T. 5, № 1.- S. 7-33.
59. Bulekov I.S. Narkopotreblenie kak glavnyi element nepriverzhennosti VAART. Mozhno li sformirovat' priverzhennost' u aktivnogo narkopotrebitelya // VICh-infektsiya i immunosupressii.- 2011.- T. 3, № 4.- S. 20-23.
60. Tkachenko T.N., Fishman B.B., Fomenko L.A. Kharakteristika psikhicheskogo statusa i povedencheskikh reaktsii u VICh-infitsirovannykh patsientov // VICh-infektsiya i immunosupressii.- 2010.- T. 2, № 1.- S. 65-69.
61. Neironauki i VICh-infektsiya: Meditsinskii tematicheskii arkhiv / Pod red N.A.Belyakova, T.N.Trofimovoi i V.V.Rassokhina. SPb.: Baltiiskii meditsinskii obrazovatel'nyi tsentr. 2013.- № 5.- 306 s.
62. Koshkina E.A., Bobkov E.N., Kirzhanova V.V. Sravnitel'noe izuchenie modelei narkoticheskogo povedeniya i pokazatelei sotsial'nogo funktsionirovaniya sredi potrebitelei opioidov i kannabinoidov // Narkologiya.- 2013.- № 7.- S. 41-49
63. Rekomendatsii Evropeiskogo klinicheskogo obshchestva SPIDa (EACS).- Versiya 6.1 - Noyabr' 2012 g.- 82 s.- URL: http://www.eacsociety.org/Portals/0/files/pdf files/Guidelines Pdf/EACSGuidelines-v6.1-Russian.pdf.
Review
For citations:
Uliukin I.M. INTERACTIONS BETWEEN ANTIRETROVIRAL AND PSYCHOACTIVE DRUGS. HIV Infection and Immunosuppressive Disorders. 2014;6(1):19-27. (In Russ.) https://doi.org/10.22328/2077-9828-2014-6-1-19-27